FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2119317963> ?p ?o ?g. }

• W2119317963 endingPage "999" @default.
• W2119317963 startingPage "992" @default.
• W2119317963 abstract "Purpose Approximately 1% of lung adenocarcinomas are driven by oncogenic ROS1 rearrangement. Crizotinib is a potent inhibitor of both ROS1 and ALK kinase domains. Patients and Methods In the absence of a prospective clinical trial in Europe, we conducted a retrospective study in centers that tested for ROS1 rearrangement. Eligible patients had stage IV lung adenocarcinoma, had ROS1 rearrangement according to fluorescent in situ hybridization, and had received crizotinib therapy through an individual off-label use. Best response was assessed locally using RECIST (version 1.1). All other data were analyzed centrally. Results We identified 32 eligible patients. One patient was excluded because next-generation sequencing was negative for ROS1 fusion. Median age was 50.5 years, 64.5% of patients were women, and 67.7% were never-smokers. Thirty patients were evaluable for progression-free survival (PFS), and 29 patients were evaluable for best response. We observed four patients with disease progression, two patients with stable disease, and objective response in 24 patients, including five complete responses (overall response rate, 80%; disease control rate, 86.7%). Median PFS was 9.1 months, and the PFS rate at 12 months was 44%. No unexpected adverse effects were observed. Twenty-six patients received pemetrexed (either alone or in combination with platinum and either before or after crizotinib) and had a response rate of 57.7% and a median PFS of 7.2 months. Conclusion Crizotinib was highly active at treating lung cancer in patients with a ROS1 rearrangement, suggesting that patients with lung adenocarcinomas should be tested for ROS1. Prospective clinical trials with crizotinib and other ROS1 inhibitors are ongoing or planned." @default.
• W2119317963 created "2016-06-24" @default.
• W2119317963 creator A5001928949 @default.
• W2119317963 creator A5003424696 @default.
• W2119317963 creator A5007155024 @default.
• W2119317963 creator A5008403882 @default.
• W2119317963 creator A5010576809 @default.
• W2119317963 creator A5016567527 @default.
• W2119317963 creator A5016904876 @default.
• W2119317963 creator A5016911330 @default.
• W2119317963 creator A5020223648 @default.
• W2119317963 creator A5023794502 @default.
• W2119317963 creator A5025511599 @default.
• W2119317963 creator A5031612498 @default.
• W2119317963 creator A5036805898 @default.
• W2119317963 creator A5040544006 @default.
• W2119317963 creator A5047940549 @default.
• W2119317963 creator A5052066844 @default.
• W2119317963 creator A5055246540 @default.
• W2119317963 creator A5056761497 @default.
• W2119317963 creator A5058511375 @default.
• W2119317963 creator A5059808734 @default.
• W2119317963 creator A5063103135 @default.
• W2119317963 creator A5069349994 @default.
• W2119317963 creator A5070375776 @default.
• W2119317963 creator A5070551146 @default.
• W2119317963 creator A5087836238 @default.
• W2119317963 date "2015-03-20" @default.
• W2119317963 modified "2023-10-17" @default.
• W2119317963 title "Crizotinib Therapy for Advanced Lung Adenocarcinoma and a <i>ROS1</i> Rearrangement: Results From the EUROS1 Cohort" @default.
• W2119317963 cites W1972906160 @default.
• W2119317963 cites W1977339134 @default.
• W2119317963 cites W1981626262 @default.
• W2119317963 cites W1982158259 @default.
• W2119317963 cites W1990626198 @default.
• W2119317963 cites W1994384682 @default.
• W2119317963 cites W2006164250 @default.
• W2119317963 cites W2015015957 @default.
• W2119317963 cites W2019926749 @default.
• W2119317963 cites W2022245544 @default.
• W2119317963 cites W2022319775 @default.
• W2119317963 cites W2049674541 @default.
• W2119317963 cites W2050249255 @default.
• W2119317963 cites W2060688738 @default.
• W2119317963 cites W2061820313 @default.
• W2119317963 cites W2062480689 @default.
• W2119317963 cites W2065799563 @default.
• W2119317963 cites W2084993196 @default.
• W2119317963 cites W2087111854 @default.
• W2119317963 cites W2088301149 @default.
• W2119317963 cites W2088720324 @default.
• W2119317963 cites W2096198395 @default.
• W2119317963 cites W2099188024 @default.
• W2119317963 cites W2103447891 @default.
• W2119317963 cites W2104830962 @default.
• W2119317963 cites W2110024096 @default.
• W2119317963 cites W2111662961 @default.
• W2119317963 cites W2112854176 @default.
• W2119317963 cites W2113762115 @default.
• W2119317963 cites W2114784462 @default.
• W2119317963 cites W2124502961 @default.
• W2119317963 cites W2126661558 @default.
• W2119317963 cites W2127129900 @default.
• W2119317963 cites W2127707247 @default.
• W2119317963 cites W2130488043 @default.
• W2119317963 cites W2132578211 @default.
• W2119317963 cites W2145950952 @default.
• W2119317963 cites W2148332636 @default.
• W2119317963 cites W2154678665 @default.
• W2119317963 cites W2166084034 @default.
• W2119317963 cites W2168691181 @default.
• W2119317963 cites W2171342019 @default.
• W2119317963 cites W2324850882 @default.
• W2119317963 cites W2327437619 @default.
• W2119317963 cites W2414966677 @default.
• W2119317963 cites W4384455562 @default.
• W2119317963 doi "https://doi.org/10.1200/jco.2014.58.3302" @default.
• W2119317963 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25667280" @default.
• W2119317963 hasPublicationYear "2015" @default.
• W2119317963 type Work @default.
• W2119317963 sameAs 2119317963 @default.
• W2119317963 citedByCount "304" @default.
• W2119317963 countsByYear W21193179632014 @default.
• W2119317963 countsByYear W21193179632015 @default.
• W2119317963 countsByYear W21193179632016 @default.
• W2119317963 countsByYear W21193179632017 @default.
• W2119317963 countsByYear W21193179632018 @default.
• W2119317963 countsByYear W21193179632019 @default.
• W2119317963 countsByYear W21193179632020 @default.
• W2119317963 countsByYear W21193179632021 @default.
• W2119317963 countsByYear W21193179632022 @default.
• W2119317963 countsByYear W21193179632023 @default.
• W2119317963 crossrefType "journal-article" @default.
• W2119317963 hasAuthorship W2119317963A5001928949 @default.
• W2119317963 hasAuthorship W2119317963A5003424696 @default.
• W2119317963 hasAuthorship W2119317963A5007155024 @default.
• W2119317963 hasAuthorship W2119317963A5008403882 @default.
• W2119317963 hasAuthorship W2119317963A5010576809 @default.

• next